FY2025 · ended Sep 30, 2025 · Revenue $65.32M, -3.4% YoY · Filed Nov 19, 2025
Enanta Pharmaceuticals, Inc (ENTA) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Sep 30, 2025, it reported revenue of $65.3 million and a net loss of $81.9 million. Free cash flow was -$32.2 million. As of Jun 30, 2026 it held $211.5 million in cash and investments and $55.7 million in total debt.
Revenue (TTM)
$65.26M
+0.7% vs year-ago TTM
Net income (TTM)
$-63.23M
+31.3% vs year-ago TTM
Operating cash flow (TTM)
$-35.32M
-52.3% vs year-ago TTM
Free cash flow (TTM)
$-36.94M
+15.2% vs year-ago TTM
EPS (TTM)
$-11.04
+98.9% vs year-ago TTM
Dividend per share
None
Shares outstanding
28.86M
+36.2% vs prior year
Net cash
$155.84M
as of Jun 30, 2026
Operating margin
-90.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENTA (Nasdaq)
- Fiscal year ends
- September 30
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1177648
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Sep 30, 2025 |
FY 2024 Sep 30, 2024 |
FY 2023 Sep 30, 2023 |
FY 2022 Sep 30, 2022 |
FY 2021 Sep 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M |
| Operating income | -$85.3M | -$121.7M | -$137.2M | -$123.8M | -$109.6M |
| Net income | -$81.9M | -$116.0M | -$133.8M | -$121.8M | -$79.0M |
| Diluted EPS | -$3.84 | -$5.48 | -$6.38 | -$5.91 | -$3.92 |
| Operating cash flow | -$19.3M | -$78.8M | -$103.2M | -$84.8M | -$70.0M |
| Free cash flow | -$32.2M | -$96.7M | -$112.2M | -$86.9M | -$70.7M |
| Total assets | $280.7M | $376.7M | $462.3M | $375.4M | $438.8M |
| Total liabilities | $216.0M | $247.8M | $245.5M | $54.1M | $39.4M |
| Stockholders' equity | $64.7M | $128.8M | $216.7M | $321.3M | $399.4M |
| Cash and investments | $188.9M | $248.2M | $369.9M | $278.5M | $352.4M |
| Total debt | $57.9M | $55.5M | $26.5M | $25.3M | $5.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 2, 2026 | Jul 2, 2026 |
| 8-K |
Current report
Other events
|
Jun 23, 2026 | Jun 23, 2026 |
All 835 Enanta Pharmaceuticals, Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.